URAT1 inhibitor 3 是一种口服有效的选择性URAT1抑制剂，其IC50值为 0.8 nM。URAT1 inhibitor 3 具有降低尿酸的作用。URAT1 inhibitor 3 可用于痛风和高尿酸血症的研究。

URAT1 inhibitor 3 is a potent, orally active, selective URAT1 inhibitor with an IC 50 value of 0.8 nM. URAT1 inhibitor 3 has urate-lowering efficacy. URAT1 inhibitor 3 can be used in research of gout and hyperuricemi [1].

URAT1 inhibitor 3 (0-400 μM; 24 and 72 h; HepG2 and HK2 cells) has low toxicity and inhibits cell viability at high concentrations [1]. URAT1 inhibitor 3 (0.01-100 μM) has lower inhibition on urate excretion transporters with IC 50 values of 10.16 μM and 4.04 μM of OAT1 and ABCG2, respectively [1]. Cell Viability Assay [1] Cell Line: HepG2 and HK2 cells Concentration: 0, 100, 200, 300, and 400 μM Incubation Time: 24 and 72 hours Result: Had little cytotoxicity at 24 h and inhibition rate of 34.75% and 35.9% of HepG2 and HK2 cells, respectively.

URAT1 inhibitor 3 (1-4 mg/kg; i.g.; once) has urate lowering efficacy in a mouse model of hyperuricemia [1]. URAT1 inhibitor 3 (50 mg/kg; i.g.; daily, for 14 d) has no hepatic and renal toxicities in mice [1]. URAT1 inhibitor 3 (50 mg/kg; i.g.; once) induces GSH depletion in Kunming mice with hyperuricemia model [1]. Animal Model: Male Kunming (KM) mice with hyperuricemia model [1] Dosage: 1, 2, and 4 mg/kg Administration: Oral gavage; once Result: Decreased the serum urate levels in a dose-dependent manner. Animal Model: Male Kunming mice [1] Dosage: 50 mg/kg Administration: Oral gavage; daily, for 14 days Result: Did not cause renal toxicity. Animal Model: Male Kunming mice with hyperuricemia model [1] Dosage: 50 mg/kg Administration: Oral gavage; once Result: Decreased the serum GSH levels from 42.23 μM to 20.39 μM.

C14H8Cl2N2O2

307.13

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years